The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

CVS Health Corporation (NYSE:CVS) is one of the undervalued large cap stocks to buy. On March 25, UBS analyst Kevin Caliendo reiterated a Buy rating and $97 price target on CVS Health Corporation (NYSE:CVS).

Source:pexels

Caliendo said that CVS’s proposed settlement with the Federal Trade Commission (FTC) over insulin pricing could lift a major cloud that has been hanging over the stock. The settlement relates to a lawsuit the FTC originally filed in September 2024, in which it accused three of the biggest US pharmacy benefit managers (PBMs) of manipulating insulin pricing in ways that harmed patients and consumers. The PBMs are CVS’s Caremark Rx, LLC, Cigna’s Express Scripts, and OptumRx.

On March 23, Caremark and Zinc Health Services, LLC, CVS’s group purchasing organization, jointly filed to withdraw the FTC’s complaints against the company. This came after submission and execution of a proposed consent agreement that resolves all claims against CVS’s subsidiaries. Both parties signed off on the deal, though the specific financial terms have been redacted in the docket.

Caliendo noted that if the terms of CVS’s settlement mirror those of Express Scripts’ earlier deal, the market is likely to treat this as “an overhang lifted on the stock.” Put simply, a long-standing source of investor uncertainty would be removed and potentially re-rating shares higher. He also specifically flagged that Zinc is already domiciled domestically, which could give CVS more favorable standing in how its settlement is structured relative to peers.

CVS Health Corporation (NYSE:CVS) is a healthcare company that provides pharmacy services, health insurance, and medical care solutions. Its offerings include retail and specialty pharmacy services, pharmacy benefit management, health insurance plans through Aetna, and clinical services such as in-store and virtual care.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 9 Best Gold Mining Companies to Buy With High Upside Potential and 12 Best Performing Cybersecurity Stocks in 2025.

Disclosure: None. Follow Insider Monkey on Google News.